Keep Informed on Legal and Compliance Developments Affecting Diagnostic Labs
Best practices and expert insight to help lab professionals comply with regulations and identify strategic trends in business and technology
Already a Subscriber? Log in Here
Lab Industry Advisor Subscription
Struggling with Staying Informed? In the fast-paced world of diagnostic medicine, staying updated with the latest legal, compliance, regulatory, and industry insights is crucial. Yet, finding reliable and comprehensive information can be overwhelming and time-consuming.
Lab Industry Advisor to the Rescue! Lab Industry Advisor provides comprehensive, up-to-date insights and analyses tailored to your needs. With expert commentary and actionable advice, you’ll stay ahead of the curve. No more sifting through endless sources—everything you need is right here!
Start your free trial today and see how Lab Industry Advisor can transform your approach. Get instant access to invaluable resources designed to keep you informed and competitive. Explore detailed reports, in-depth articles, and exclusive industry insights that help you make better decisions faster. Choose from three subscription levels tailored to fit your needs: Essential, Premium, and Elite.
Additional Business Intelligence Offerings
Clinical Diagnostics Insider
Keeps you up-to-date on new diagnostic tests, testing trends and opportunities, and emerging test technologies
Virtual Events & Webinars
Virtual events & webinars offer a variety of solutions and strategies for dealing with key issues labs face.
Lab Industry Advisor Subscriptions Include
Analysis and insight on key compliance, legal, and business developments affecting laboratories
- Updates on changes to regulations
- Healthcare-related laws
- FDA approvals
- Business deals in the diagnostics space, and more
Latest Articles
LDTs Rule Update: More Support for Legal Challenges Against FDA
Key clinical laboratory organizations file amicus brief, reiterating that the FDA is overstepping its authority, and its new rule would cause “irreparable patient harm”
New FDA LDTs Guidance Offers Useful Summary, But Questions Remain
Recently released document for small labs offers a more digestible version of the final rule requirements but still lacks key details
CMS Slated to Close Change Healthcare Payment Program
Program meant to ease cash flow disruptions experienced by some Medicare providers and suppliers due to the cyberattack will conclude in mid-July
CMS Proposes Modest Increase to Hospital IPPS Rates
Unsurprisingly, the American Hospital Association and other industry groups don’t think that increase is anywhere near adequate.
AI Algorithm Gets FDA Breakthrough Device Designation
The algorithm, designed to help diagnose pulmonary hypertension earlier, aims to ensure patients get treatment sooner.
What Happens to COVID Tests After Public Health Emergency Ends?
The FDA will almost certainly keep EUA tests on the market after the PHE expires.
Labs in Court Weekly Roundup
Settlements for False Claims Act allegations the theme in recent enforcement actions involving the healthcare industry.
False Billing of UDTs Remains a Prime Target for Enforcement
UDT false billing cases seem to be on the rise again, accounting for a trio of recent multimillion dollar settlements.
OIG Issues First Positive Advisory Opinion for Free Genetic Testing
On April 11, the OIG approved a proposed arrangement involving the offering of free genetic tests and counseling services.
FDA Sounds the Alarm on Counterfeit OTC COVID-19 Tests
Counterfeit COVID-19 tests are being illegally imported into the US and being distributed to unsuspecting consumers across the country.
Should Certain Racial Groups be Screened for Diabetes at Lower BMIs?
Recent study shows that different diabetes screening guidelines are required to produce equal benefits for certain racial groups.
Labs in Court Weekly Roundup
Recent health care industry-related cases involved a variety of fraud types, including kickbacks and fake vaccine card distribution.
World Leaders Promise More Funds to Fight Pandemic at COVID-19 Summit
Meeting for the second Global COVID-19 Summit, leaders from around the world made additional financial commitments to fighting the disease
